Live Breaking News & Updates on நிறுவனம் அறிக்கை ஆஃப் நிதி பொஸிஶந்

Stay updated with breaking news from நிறுவனம் அறிக்கை ஆஃப் நிதி பொஸிஶந். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Infrastrata PLC Announcements | Infrastrata PLC: Annual Report and Notice of Meeting


·
Successfully raised £7.40 million in December 2020 / January 2021
·
Significant uptick in revenue generation since September 2020; current monthly revenue generation equivalent to FY 2020 revenues
·
Cash break-even position achieved and maintained within the cruise and ferry business
·
Progress being made on large contract fabrication for renewables and defence; pre-qualification achieved and contract negotiations being undertaken 
 
 
2020 was a challenging year for the Group. When we acquired Harland & Wolff (Belfast) in December 2019, we did not expect a global pandemic to hit us and disrupt our lives so dramatically. Despite that, we have remained focussed and committed to growing our business. Our yards have been open throughout this period and we have had the privilege of welcoming over 30 vessels as at the date of this report and successfully re-deliveri ....

United Kingdom , Barrow In Furness , Irish Sea , Ireland General , Northern Ireland , City Of , Harland Wolff Belfast , John Parker , John Wood , Harland Wolff , Tarun Raman , Callum Davidson , Mark Jessop , Clive Richardson , Michael Johnson , Harland Wolff Appledore , Queen Elizabeth , Seena Shah , Head Office , Westmount Energy , Appledore Shipyard In Devon , National Shipbuilding Strategy , Owners Of The Company , National Shipbuilding Strategy For The United Kingdom , Front End Project Development , Harland Wolff Group Holdings ,

Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results


Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results
Helix or the
Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020.
OVERVIEW
The Company reported a net loss and total comprehensive loss of $222,000 for the three-month period ended October 31, 2020 (2019 - $2,214,000). Net loss and comprehensive loss for the three-month period ending October 31, 2020 included a gain from loss of control in Helix Immuno-Oncology S.A. ( HIO ) of $2,162,000 (2019 - $nil) on September 3, 2020.
On November 9, 2020, the Company announced that it has signed a definitive share purchase agreement with CAIAC Fund Management AG ( CAIAC ) to purchase the Company s remaining 29.89% holdings in Helix Immuno-Oncology S.A. ( HIO ), for gross proce ....

Richmond Hill , Pascal Nigen , Company Us Phase Ib , Moffit Cancer Center , Drug Administration , Helix Biopharma Corp , Fund Management , Alpha Bronze , Toronto Stock Exchange , Company Statement Of Financial Position , Helix Biopharma , Management Est , European Phase , Moffit Cancer , Consulting Management , Financial Position , Net Loss , Comprehensive Loss , Looking Statements , Annual Information Form , ரிச்மண்ட் மலை , பாஸ்கல் நீகெண் , நிறுவனம் எங்களுக்கு கட்டம் இப் , மோப்பித் புற்றுநோய் மையம் , நிதி மேலாண்மை , ஆல்பா வெண்கலம் ,

Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results


Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, forward-looking statements ) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company s future business, operations, research and development, including the Company s activities relating to DOS47, and other information in future periods.
Forward-looking statements include, without limitation, statements concerning (i) the Company s ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company s priority continuing to be L-DOS47; (iii) the Company s development programs for DOS47, L-DOS47, V-DOS47 and CAR-T; (iv) future expenditures, the in ....

Richmond Hill , Pascal Nigen , Company Us Phase Ib , Moffit Cancer Center , Drug Administration , Helix Biopharma Corp , Fund Management , Alpha Bronze , Toronto Stock Exchange , Company Statement Of Financial Position , Helix Biopharma , Management Est , European Phase , Moffit Cancer , Consulting Management , Financial Position , Net Loss , Comprehensive Loss , Looking Statements , Annual Information Form , ரிச்மண்ட் மலை , பாஸ்கல் நீகெண் , நிறுவனம் எங்களுக்கு கட்டம் இப் , மோப்பித் புற்றுநோய் மையம் , நிதி மேலாண்மை , ஆல்பா வெண்கலம் ,